Compare BioNTech SE - ADR (BNTX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs TKO Group Holdings Inc — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while TKO Group Holdings Inc trades at $186.72 (market cap $13.84B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.69% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TKO | |
|---|---|---|
Market Cap | $22.86B | $13.84B |
Sector | Health | Technology |
52-Week High | $119.34 | $224.96 |
52-Week Low | $83.89 | $155.61 |
Enterprise Value | $6.53B | $18.01B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
TKO Group Holdings trades at $180.96, down 1.87% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported strong Q1 2026 earnings beat but missed Q3 and Q4 2025 expectations. Revenue grew to $4.74B in 2025 with net income of $195.4M, while 2026 projections show continued growth to $5.1B revenue. Recent developments include successful international events and an $800M share repurchase completion.
Wall Street maintains strong bullish sentiment with 89% buy ratings and $228 consensus price target, representing 26% upside. Key risks include execution on earnings guidance and competitive pressures in sports entertainment. The company's premium valuation (P/E 68.6) requires sustained growth delivery, while positive cash flow trends and dividend payments provide shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
